Source comparison
Potency Comparison in Cell-Based Assays
Quantitative comparison of MT-II and PT-141 potency is receptor subtype and assay system dependent, but generalizations from the published preclinical literature include: At MC1R: MT-II is substantially more potent than PT-141 in cAMP accumulation assays at th
This comparison does not assign a generated winner or score.
- Quantitative comparison of MT-II and PT-141 potency is receptor subtype and assay system dependent, but generalizations from the published preclinical literature include:
- At MC1R: MT-II is substantially more potent than PT-141 in cAMP accumulation assays at this subtype. This is consistent with MT-II's known pan-agonist profile.
- At MC4R: Both compounds show high affinity in radioligand binding at MC4R, with EC50 values in published in vitro cAMP assays in the low to sub-nanomolar range. Direct potency comparisons vary by assay system and cell line.
- At MC3R: Both show activity, with published Ki values in the nanomolar range. Relative potency at MC3R may differ between assay systems.